Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bazedoxifene plus Conjugated Estrogens for Breast Cancer Risk Modulation
NCT04821375Phase 1Completed
- Start
- Dec 2021
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bazedoxifene and conjugated estrogens in breast cancer. Primary endpoint: Number of potential participants who consent to enrollment. Started Dec 2021; status: completed.
02
Drugs
bazedoxifeneconjugated estrogens
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04821375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04821375.